Definium Therapeutics, Inc. last reported quarterly results on Aug 6, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): diluted EPS of -$1.44. It usually reports 12–37 days after a quarter ends. Based on that pattern, the next release is estimated for around Oct 28, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Oct 29, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–37 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
—
|
-159
-271.9%
|
-1.44
-188.0%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
—
|
-77
-230.2%
|
-0.71
-102.9%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
—
|
-50
-45.2%
|
-0.50
-20.8%
|
|
Oct 29, 2025
29 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
—
|
-67
-391.6%
|
-0.78
-188.9%
|
|
Jul 31, 2025
31 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
—
|
-43
-630.2%
|
-0.50
-92.3%
|
|
May 8, 2025
38 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
—
|
-23
+57.1%
|
-0.35
+69.3%
|
|
Mar 6, 2025
65 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
—
|
-35
-45.6%
|
-0.41
+30.2%
|
|
Nov 7, 2024
38 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
—
|
-14
+23.7%
|
-0.27
+40.0%
|
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- DFTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- New York, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1813814
- Former names
- Mind Medicine (MindMed) Inc. (until Jan 12, 2026)
Other Medicinal Chemicals & Botanical Products companies
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
- Aurora Cannabis Inc ACB
Source: SEC EDGAR filings. This is company-reported data, not investment advice.